"They're betting on a lot of things going right, " says Jeffrey Peters, analyst with Dain Rauscher Wessels.

FORBES: Which Conglomerators Are the Big Winners?

Byrnes, a pharmaceutical analyst at Dain Rauscher Wessels, said as much in a report earlier this week.

FORBES: Top Of The News: Life Sciences Dying

In justifying his strong buy rating on the company, Carl Byrns at Dain Rauscher Wessels points to an anti-viral drug: Peg-intron plus ribavirin combination therapy for Hepatitis C.

FORBES: Dog Watch: Schering-Plough

Carl Byrnes, an analyst at Dain Rauscher Wessels, has worried that Pravachol will face new pressure when AstraZeneca (nyse: AZN - news - people) introduces its new Crestor cholesterol drug next year.

FORBES: Magazine Article

In 2008, Royal Bank of Canada and FBW announced a merger agreement whereby RBC Dain Rauscher Inc. acquired FBW. Subsequently, Kuta subsequently was registered with FINRA member firm RBC Capital Markets Corporation from March through September 2009.

FORBES: Claimant Sues RBC for $37 Million BUT FINRA Panel Hits Him For $1.8 Million

But Carl Byrnes, an analyst at Dain Rauscher Wessels, worries that it will lose market share in the face of Pfizer 's (nyse: PFE - news - people) Geodon, a new anti-psychotic introduced in March.

FORBES: Magazine Article